Asahi Kasei Pharma

In March 2016, Array announced a strategic collaboration with Asahi Kasei Pharma Corporation (AKP) to develop and commercialize select preclinical tropomyosin receptor kinase A (TrkA) inhibitors, including Array-invented AK-1830 (ARRY-954), for pain, inflammation, and other non-cancer diseases. AK-1830 is currently advancing in a Phase 1 trial in Japan. Array retains full commercialization rights for all compounds in all indications in territories outside of Asia. Within Asia, Array retains full rights to cancer indications for all compounds excluding those being developed by AKP.